Relmada Therapeutics Inc Stock

$2.76

1.43% yesterday

Nasdaq, Nov 25, 10:00 pm CET

ISIN

US75955J2042

Symbol

RLMD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Relmada Therapeutics Inc Stock price

$2.76

-26.72 90.64% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

-0.04 1.43%

ISIN

US75955J2042

Symbol

RLMD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$83.28m
Enterprise Value	$29.16m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	1.75
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-91.64m
Free Cash Flow (TTM) Free Cash Flow	$-53.21m
Cash position	$54.12m
EPS (TTM) EPS	$-2.87
P/E forward	negative
Short interest	4.23%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Relmada Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

4 Analysts have issued a Relmada Therapeutics Inc forecast:

3x Buy

75%

1x Sell

25%

More details on Analyst Estimates Including Price Targets

4 Analysts have issued a Relmada Therapeutics Inc forecast:

Buy

75%

Sell

25%

Analyst Estimates with Stock Price Targets

Financial data from Relmada Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	42 42	14% 14% -
- Research and Development Expense	50 50	25% 25% -
EBITDA	-92 -92	21% 21% -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-92 -92	21% 21% -
Net Profit	-86 -86	22% 22% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Relmada Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

5 days ago

Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm

NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Relmada Therapeutics, Inc. (NASDAQ: RLMD) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.

Neutral

GlobeNewsWire

●

12 days ago

Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease

REL-P11 is a proprietary, low-dose, modified-release psilocybin formulation Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in obese and normal weight subjects With positive results, Phase 2a proof-of-concept study expected to begin in H1 2025 CORAL GABLES, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a ...

Neutral

Seeking Alpha

●

16 days ago

Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q3 2024 Earnings Call November 7, 2024 4:30 PM ET Company Participants Tim McCarthy - Investor Relations Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Operator Hello and welcome to the Relmada Therapeutics Third Quarter 2024 Earnings Conference Call. [Operator Inst...

More Relmada Therapeutics Inc News

Company Profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.

Head office	United States
CEO	Sergio Traversa
Employees	20
Founded	2012
Website	www.relmada.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now